Correction: Masitinib for mild-to-moderate Alzheimer’s disease: results from a randomized, placebo-controlled, phase 3, clinical trial - Bruno Dubois; Jesús López‑Arrieta; Stanley Lipschitz; Triantafyllos Doskas; Luiza Spiru; Svitlana Moroz; Olena Venger; Patrick Vermersch; Alain Moussy; Colin D. Mansfield; Olivier Hermine; Magda Tsolaki; et al. (Alzheimer’s Research & Therapy, 2023)